据悉，德生科技与广州医保联合打造的"就医无感支付"项目，在刚刚过去的2025全国智慧医保大赛评选 中获得一等奖。 本报讯 （记者李昱丞）据国家医疗保障局1月8日微信公众号消息，国家医疗保障局办公室发布《关于 大力推进刷脸支付、一码支付、移动支付、信用支付等便捷支付工作的通知》。通知聚焦群众看病缴 费"多次排队""排长队"等堵点痛点，明确加快推进刷脸支付、一码支付、移动支付、信用支付在各类医 疗场景落地，力争用3年左右时间全面建成医保便捷支付体系。按照部署，各省份将于2026年实现首批 推进地区和定点医疗机构落地见效，2027年基本实现省内统筹地区全覆盖，2028年在符合条件的定点医 疗机构全面推广。 对此，广东德生科技股份有限公司（以下简称"德生科技"）方面称，公司在"就医无感支付"服务的创新 实践，与此政策高度契合。公司凭借在医疗领域的数字赋能和服务成效，正加速构建AI医疗应用生 态，全面助力医疗服务向数字化、智能化跃迁。 （编辑 黄力） ...

2025年12月30日，南京韩美维媞整形医院项目在建邺区金融城二期举行开工仪式。活动现场完成院区设计方案发布、落地政策协议签署及揭幕礼等环节， 标志着项目建设进入实质化推进阶段。 建邺区副区长孔南钢，南京市商务局党组成员、南京市投资促进中心主任王威，南京市商务局外国投资管理处处长胡滨，建邺区沙洲街道党工委副书记、 办事处主任林海，建邺区街道办事处副主任陈波，金融城公司党支部书记、董事长贺华，M&J医疗集团中国区投资总裁肖瑶、商务负责人戴越、总裁助 理JANG YEONJI，以及江苏省规划设计集团建筑设计院副院长朱道焓等出席。 M&J医疗集团中国区总裁肖瑶致辞中表示，南京韩美维媞整形医院由M&J医疗集团通过新加坡VITA健康有限公司在南京全资建设，总投资约1,000万美 元，项目位于建邺区金融城二期，建筑面积约8,700平方米，规划床位120张，拟配备约250人的专业医疗团队，力争于2026年一季度启动运营。项目顺应 国家允许设立外商独资医院的政策导向，旨在引进国际高水平医疗资源、丰富本地高品质医疗服务供给。 配图——大厅效果图 在建设推进方面，项目坚持"方案成熟一项、推进一项"。医疗空间与工艺将严格按洁净手术 ...

据悉，美敦力北京数字化医疗创新基地是全球首个聚焦医疗科普与患者服务的主题创新空间，自2025年10月正式 启用以来，打造了集科技展示、科普教育、患者互动、远程服务于一体的多功能平台。基地内特设美敦力博物 馆，不仅收藏着全球第一台电池驱动的体外心脏起搏器等珍贵展品，还系统呈现医疗技术迭代历程和智能化未来 愿景；还规划了数字疗法患者体验区、互动空间等专属区域，既为患者提供近距离接触前沿医疗科技的窗口，也 为医患沟通、患者互助搭建了实体桥梁。 出席此次活动的所有患者都是美敦力心律失常患者数字化全周期服务平台——"美敦力心律管家"的用户，该平台 以患者需求为核心，整合了远程随访、健康知识科普、术后康复指导、线上社群交流等多重功能，通过"线上+线 下"联动模式，为患者提供从术后随访到长期健康管理的一站式支持。目前该平台的注册者已经超过15万人。 本次活动中，心律失常患者代表参观了创新基地内的美敦力博物馆。从全球第一台电池驱动的体外心脏起搏器原 型，到如今胶囊大小的无导线心脏起搏器，一件件跨越数十年的医疗设备，清晰呈现了心律失常治疗技术的迭代 轨迹。"没想到起搏器能从那么大一台，变成现在几乎不影响生活的样子。"一位植入起 ...

"以前在不同的医院做同样的检查，费用得重复交，结果还要等好长时间才能拿到。"家住宝鸡市渭 滨区的李晓宁说，她前不久在宝鸡市人民医院做了血常规检查。这次去宝鸡市中医医院看诊时，医生直 接从全市医学检验结果共享互认信息平台调取了结果，让她省时又省钱。 今年初，为解决患者在不同医疗机构就诊时多头检查、重复检验问题，宝鸡市卫生健康委启动了全 市医学检验结果共享互认信息平台建设工作，通过统一全市检验报告数据标准，建立实时上传与共享机 制，搭建互联互认安全数据平台，全面打通了宝鸡市医疗机构间的检验数据壁垒，实现检验结果的高效 互认与调阅。 12月20日，记者从宝鸡市卫生健康委获悉：宝鸡市通过建设医学检验结果共享互认信息平台，今年 实现了101项检验项目"跨院通用"，累计服务患者6.21万人次，节省检验费用319.8万元。 宝鸡市卫生健康委副主任宁海波表示，宝鸡市将进一步扩大机构互认范围，优化升级平台便民惠民 服务功能，结合正在试点实施的陕西省"三秦智医助理"系统重点建设项目，在便民、助医、辅政、促研 4个方面持续发力，让更多数字化、智能化卫生健康建设成果惠及群众。 （记者：李静茹） 截至目前，该平台一期项目已接入全市40 ...

Core Viewpoint - Jinan City is focusing on high-quality development in health care during the "14th Five-Year Plan" period, leveraging digital technology to address issues such as difficulty in accessing medical services and long waiting times [3] Group 1: Digital Health Initiatives - Jinan has established itself as a "demonstration city" for "Internet + Medical Health," utilizing digital and intelligent technologies to enhance health service processes, making medical visits more convenient and efficient [3] - The city has built a "regional imaging cloud platform" that allows for the sharing of medical imaging results across hospitals, eliminating the need for patients to carry physical films, with over 70,000 mutual recognitions achieved since the system's launch, saving patients over 50 million yuan [3] - The "electrocardiogram network" has achieved full coverage in districts and counties, completing over 400,000 remote diagnoses and successfully treating more than 20,000 chest pain patients, providing timely expert diagnoses at the grassroots level [3] Group 2: Artificial Intelligence in Healthcare - The first China Medical Artificial Intelligence Conference was successfully held in Jinan, promoting the application of AI in medical services, which has effectively reduced waiting times in hospitals [4] - A unified computing power platform has been established to support 13 medical institutions, with over 3 billion calls made, reducing the costs and burdens of individual deployments [4] - AI-assisted diagnosis has provided over 40 million instances of decision support in imaging and pathology, with an electronic medical record standardization rate of 89.9%, significantly enhancing the capabilities and service levels of primary care [4] Group 3: Public Health and Community Services - A foodborne disease monitoring information system has been developed, allowing for "one-click reporting" and covering over 160 grassroots health institutions, which is crucial for early warning and efficient handling of public health emergencies [4] - Online services have been enriched to optimize appointment scheduling, in-clinic settlements, drug delivery, and result notifications, while pilot programs for digital prescriptions for adult vaccinations have been initiated in 29 community health service centers [4]

Core Insights - Bayer has officially launched its first innovation center in China, the Bayer Yizhuang Open Innovation Center, marking a strategic shift in the perception of China from a large market to an innovation hub [1][3] - The center aims to integrate local innovation resources and accelerate the deep integration of industry, academia, and research, focusing on innovative drugs in areas such as cardiovascular diseases and oncology [1][3] Group 1 - The Bayer Yizhuang Open Innovation Center is a significant strategic milestone for Bayer in China, serving as a core hub for collaboration with local innovation forces [3] - The center is expected to foster a series of collaborative outcomes and support Chinese companies in expanding internationally [3] - The launch coincided with a themed event that gathered top scientists, scholars, and business leaders from China and Europe to discuss topics such as digital healthcare and the clinical translation of research results [3]

Core Insights - The 8th China International Import Expo (CIIE) opened on November 5, showcasing Roche's commitment to innovation and life protection with over 40 products and diverse innovative solutions [1][3] - Roche's participation highlights the importance of CIIE as a strategic platform for foreign enterprises to engage with the Chinese market and share global innovations [5] Group 1: Roche's Participation - Roche Pharmaceuticals held the "2025 Roche Pharmaceuticals 8th CIIE Opening Ceremony" and presented its complete pharmaceutical value chain in China for the first time [1] - The company showcased more than 10 products that will soon be launched in China, covering various disease areas including breast cancer, hematology, neuroscience, ophthalmology, immunology, cardiovascular, and metabolism [5] Group 2: CIIE's Role - The CIIE serves as a key platform for China to open its market and promote global cooperation, focusing on high-quality exhibitors and innovative products [3] - Over the past eight years, the CIIE has facilitated the transformation of nearly 15 Roche global innovative drugs from exhibits to market-ready products, benefiting Chinese patients [5] Group 3: Innovative Solutions - Roche's exhibition included immersive creative interactive installations to enhance public understanding of medical innovations and humanistic care [5] - The company also presented various AI solutions that span research, diagnosis, and patient management, aiming to empower the entire diagnostic and treatment process [5]

Core Insights - The China International Import Expo (CIIE) has transformed companies from exhibitors to investors, showcasing China's vast market potential and encouraging innovation [1][2] - Medtronic has participated in CIIE for eight consecutive years, launching over 70 new products, with 33 of them being introduced in China [1] - The establishment of Medtronic's first digital healthcare innovation base in Beijing highlights the rapid development and collaboration opportunities in AI and big data [1] Group 1: CIIE Impact - CIIE serves as a platform for global companies to enter the Chinese market, with 290 Fortune 500 and industry-leading companies participating in the ongoing eighth edition [1] - The expo has facilitated the localization of products, enabling them to quickly enter the Chinese market and expand globally [2] Group 2: Medtronic's Innovations - Medtronic showcased one global premiere, one Asia-Pacific premiere, and five China premieres at this year's CIIE, including the Inceptiv spinal cord stimulation system [2] - The company aims to integrate into the local innovation ecosystem, supporting Chinese innovative enterprises in their global expansion [2]

Core Viewpoint - Becton, Dickinson and Company (BD) demonstrates "steady growth and structural optimization" in its financial performance amidst challenges in the global medical device industry, showcasing its strategic adjustments and defensive positioning in a complex environment [2][14]. Financial Performance Q4 Performance - In Q4 of FY2025, BD achieved revenues of $5.9 billion (approximately 42 billion RMB), representing an 8.3% year-over-year increase, with organic growth of about 3.9%. The performance slightly exceeded market expectations, reflecting stable profit margins [3][4]. - BD Medical segment reported revenues of approximately $3.155 billion, a year-over-year increase of 11.2%, with organic growth of 4.0%, driven by a recovery in demand for drug infusion and delivery systems [4][8]. - Adjusted operating profit margin improved to around 25%, benefiting from product mix optimization and cost control, with healthy cash flow and approximately $2.2 billion returned to shareholders through dividends and buybacks [5]. Annual Performance - For FY2025, BD reported total revenues of approximately $21.8 billion, an 8.2% year-over-year increase, with foreign currency neutral growth of 7.7% and organic growth of about 2.9%. Adjusted diluted earnings per share were $14.40, reflecting a 9.6% increase [6][8]. Business Segments - BD Medical segment maintained robust growth, driven by drug infusion and safety injection systems, which continue to be the company's core cash flow generators [8]. - BD Life Sciences segment reported revenues of approximately $1.368 billion, a 2.1% year-over-year increase, with organic growth of 0.3%, as demand for COVID-related products declined [8]. - BD Interventional segment emerged as the fastest-growing business unit, with revenues of approximately $1.367 billion, an 8.5% year-over-year increase, driven by strong performance in vascular intervention and surgical systems [8]. Strategic and Innovation Layout - BD is advancing a dual-path strategy of "core strengthening and emerging breakthroughs," focusing on supply chain optimization and increased investment in digital and intelligent healthcare solutions [10]. - The company is accelerating its transformation towards an integrated model of "equipment + data + services," particularly in drug management and infusion systems [10]. Global Market and Regional Strategy - North America remains a strong growth market for BD, contributing significantly to revenue and profit, while emerging markets show mixed growth, with strong performance in India and Latin America, but slower growth in China due to policy and pricing pressures [11][12]. Operational and Cost Management - BD's "BD Excellence" operational optimization plan focuses on production automation, process streamlining, energy management, and sustainable supply chain practices, helping maintain profit margins amid inflation and currency fluctuations [13]. Conclusion - Overall, BD's FY2025 financial report reflects a "steady yet progressive and structurally differentiated" performance, with traditional businesses showing resilience and innovative segments entering a growth phase [14][15]. The report signals a normalization of global medical demand, with core consumables and interventional devices remaining growth pillars [14].

Group 1 - The 8th China International Import Expo (CIIE) opened on November 5, showcasing Roche's commitment to innovation and life protection with over 40 products and innovative solutions [1][2] - Roche's participation in CIIE has facilitated the transformation of nearly 15 global innovative drugs into marketable products in China, benefiting local patients [2] - Roche's exhibition includes upcoming products in various disease areas such as breast cancer, hematology, neuroscience, ophthalmology, immunology, cardiovascular, and metabolism [2][3] Group 2 - The CIIE serves as a key platform for China's market openness and global cooperation, emphasizing high-quality exhibitors and innovative products [2] - Roche's exhibition features immersive interactive installations and a "healing space" to enhance public engagement with medical innovations and humanistic care [2] - During the expo, Roche and its partners held over ten conferences focusing on digital healthcare and medical innovation, showcasing the latest clinical advancements and cross-sector collaboration [3]